Over-Expression of CD200 Predicts Poor Prognosis in Cutaneous Squamous Cell Carcinoma

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2016 Apr 2

PMID 27035797

Citations 5

Authors

Li Li

Yanli Tian

Chengfang Shi

Hua Zhang

Zhi Zhou

Affiliations

Soon will be listed here.

Abstract

Background: CD200 is reported to be involved in tumor progression and can serve as a prognostic marker in several cancers. The purpose of this study was to evaluate the prognostic significance of CD200 in cutaneous squamous cell carcinoma (CSCC).

Material/methods: The relative mRNA and protein expression of CD200 in the tumor tissues and corresponding normal tissues of 102 CSCC patients were detected by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis, respectively. The chi-square test was used to analyze the association between CD200 expression and clinical features of CSCC patients. In addition, the overall survival of the patients according to the expression level of CD200 was estimated by Kaplan-Meier analysis and the prognostic significance of the gene was analyzed by Cox regression analysis.

Results: Increased expression of CD200 was detected in the tumor tissues compared with the corresponding normal tissues both at mRNA and protein level. And CD200 expression level was associated with tumor differentiation grade (P=0.041) and clinical stage (P=0.004). Patients with high expression level of CD200 had a shorter overall survival than those with low expression (31.3 months vs. 41.9 months) and there was a significant difference between them (log-rank test, P<0.001). Cox regression analysis indicated that CD200 could be an independent marker for the prognosis of CSCC.

Conclusions: CD200 is up-regulated and may be a novel biomarker for the prognosis in CSCC, and it may be a potential therapeutic target for CSCC.

Citing Articles

Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies.

Baek S, Cui K Int J Mol Sci. 2025; 26(1.

PMID: 39795972 PMC: 11719565. DOI: 10.3390/ijms26010115.

CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy.

Nip C, Wang L, Liu C Biomedicines. 2023; 11(12).

PMID: 38137547 PMC: 10741515. DOI: 10.3390/biomedicines11123326.

Promising Markers in the Context of Mesenchymal Stem/Stromal Cells Subpopulations with Unique Properties.

Smolinska A, Bzinkowska A, Rybkowska P, Chodkowska M, Sarnowska A Stem Cells Int. 2023; 2023:1842958.

PMID: 37771549 PMC: 10533301. DOI: 10.1155/2023/1842958.

The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy.

Shao A, Owens D Oncotarget. 2023; 14:96-103.

PMID: 36738455 PMC: 9899099. DOI: 10.18632/oncotarget.28354.

Identification of a novel conserved signaling motif in CD200 receptor required for its inhibitory function.

Timmerman L, de Graaf J, Satravelas N, Kesmir C, Meyaard L, van der Vlist M PLoS One. 2021; 16(3):e0244770.

PMID: 33780466 PMC: 8007030. DOI: 10.1371/journal.pone.0244770.

References

Douds J, Long D, Kim A, Li S . Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma. J Clin Pathol. 2014; 67(9):792-6. DOI: 10.1136/jclinpath-2014-202421. View

Zhang X, Shen A, Guo R, Wang Y, Qiu H, Qiao C . [Expression characteristics of CD200 in acute myeloid leukemia and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014; 22(6):1531-4. DOI: 10.7534/j.issn.1009-2137.2014.06.006. View

Vinicius D, Scapulatempo C, Perpetuo N, Mohamed F, de Carvalho T, de Oliveira A . Prognostic and risk factors in patients with locally advanced cutaneous squamous cell carcinoma of the trunk and extremities. J Skin Cancer. 2011; 2011:420796. PMC: 3135120. DOI: 10.1155/2011/420796. View

Akman-Karakas A, Yalcin A, Koc S, Gumuslu S, Senol Y, Ozkesici B . There might be a role for CD200 in the pathogenesis of autoimmune and inflammatory skin disorders. Med Sci Monit. 2013; 19:888-91. PMC: 3809986. DOI: 10.12659/MSM.889624. View

Meuth S, Simon O, Grimm A, Melzer N, Herrmann A, Spitzer P . CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol. 2008; 194(1-2):62-9. DOI: 10.1016/j.jneuroim.2007.11.013. View

Vela-Ojeda J, Garcia-Ruiz Esparza M, Padilla-Gonzalez Y, Perez-Retiguin F, Reyes-Maldonado E, Maillet D . [CD200 protein, bad prognostic in patients with multiple myeloma]. Rev Med Inst Mex Seguro Soc. 2015; 53(4):438-43. View

Belkin D, Mitsui H, Wang C, Gonzalez J, Zhang S, Shah K . CD200 upregulation in vascular endothelium surrounding cutaneous squamous cell carcinoma. JAMA Dermatol. 2013; 149(2):178-86. DOI: 10.1001/jamadermatol.2013.1609. View

Talebian F, Bai X . The role of tumor expression of CD200 in tumor formation, metastasis and susceptibility to T lymphocyte adoptive transfer therapy. Oncoimmunology. 2012; 1(6):971-973. PMC: 3489763. DOI: 10.4161/onci.20034. View

Hoek R, Ruuls S, Murphy C, Wright G, Goddard R, Zurawski S . Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000; 290(5497):1768-71. DOI: 10.1126/science.290.5497.1768. View

10.

Podnos A, Clark D, Erin N, Yu K, Gorczynski R . Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6. Breast Cancer Res Treat. 2012; 136(1):117-27. DOI: 10.1007/s10549-012-2258-3. View

11.

Aref S, Azmy E, El-Gilany A . Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. Hematol Oncol. 2015; 35(1):51-57. DOI: 10.1002/hon.2206. View

12.

Estep R, Rawlings S, Li H, Manoharan M, Blaine E, OConnor M . The rhesus rhadinovirus CD200 homologue affects immune responses and viral loads during in vivo infection. J Virol. 2014; 88(18):10635-54. PMC: 4178886. DOI: 10.1128/JVI.01276-14. View

13.

Jung Y, Vermeer P, Vermeer D, Lee S, Goh A, Ahn H . CD200: association with cancer stem cell features and response to chemoradiation in head and neck squamous cell carcinoma. Head Neck. 2014; 37(3):327-35. PMC: 4557697. DOI: 10.1002/hed.23608. View

14.

Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden P . CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol. 2004; 172(12):7744-9. DOI: 10.4049/jimmunol.172.12.7744. View

15.

Chen M, Cai M, Luo R, Tian X, Liao Q, Zhang X . Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma. Br J Dermatol. 2014; 172(1):111-9. DOI: 10.1111/bjd.13226. View

16.

Moreaux J, Veyrune J, Reme T, De Vos J, Klein B . CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun. 2007; 366(1):117-22. DOI: 10.1016/j.bbrc.2007.11.103. View

17.

Cerroni L . Cutaneous squamous-cell carcinoma. N Engl J Med. 2001; 345(4):296; author reply 296-7. View

18.

Kwa R, Campana K, Moy R . Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992; 26(1):1-26. DOI: 10.1016/0190-9622(92)70001-v. View

19.

Yanofsky V, Mercer S, Phelps R . Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer. 2011; 2011:210813. PMC: 3018652. DOI: 10.1155/2011/210813. View

20.

Tanemura A, Nagasawa T, Inui S, Itami S . LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg. 2005; 31(4):423-30. DOI: 10.1111/j.1524-4725.2005.31108. View